Visceral leishmaniasis after treatment with immune checkpoint inhibitors

J Dtsch Dermatol Ges. 2021 Jan;19(1):119-121. doi: 10.1111/ddg.14217. Epub 2020 Aug 11.

Authors

Konstantin Drexler¹, Kirsten Utpatel², Lisa Hannah Eholzer¹, Mark Berneburg¹, Sebastian Haferkamp¹

Affiliations

¹ Department of Dermatology, University Hospital Regensburg, Germany.
² Institute of Pathology, University Regensburg, Germany.

PMID: 32783307
DOI: 10.1111/ddg.14217

No abstract available

Publication types

Letter

MeSH terms

Humans
Immune Checkpoint Inhibitors* / adverse effects
Leishmaniasis, Visceral* / diagnosis

Substances

Immune Checkpoint Inhibitors